EE200100136A - Atsetüülkoliini esteraasi inhibiitori ja psühhoosivastase toimeaine kasutamine ravimi valmistamiseks, mis on ette nähtud kognitsiooni- ja psühhoosihäirete raviks, ning neid aineid sisaldav farmatseutiline kompositsioon - Google Patents
Atsetüülkoliini esteraasi inhibiitori ja psühhoosivastase toimeaine kasutamine ravimi valmistamiseks, mis on ette nähtud kognitsiooni- ja psühhoosihäirete raviks, ning neid aineid sisaldav farmatseutiline kompositsioonInfo
- Publication number
- EE200100136A EE200100136A EEP200100136A EEP200100136A EE200100136A EE 200100136 A EE200100136 A EE 200100136A EE P200100136 A EEP200100136 A EE P200100136A EE P200100136 A EEP200100136 A EE P200100136A EE 200100136 A EE200100136 A EE 200100136A
- Authority
- EE
- Estonia
- Prior art keywords
- cognitive
- medicament
- agents
- manufacture
- treatment
- Prior art date
Links
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 title 1
- 208000028017 Psychotic disease Diseases 0.000 title 1
- 239000000164 antipsychotic agent Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 230000001149 cognitive effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98203454 | 1998-10-16 | ||
| PCT/EP1999/007804 WO2000023057A2 (en) | 1998-10-16 | 1999-10-12 | Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200100136A true EE200100136A (et) | 2002-06-17 |
Family
ID=8234219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200100136A EE200100136A (et) | 1998-10-16 | 1999-10-12 | Atsetüülkoliini esteraasi inhibiitori ja psühhoosivastase toimeaine kasutamine ravimi valmistamiseks, mis on ette nähtud kognitsiooni- ja psühhoosihäirete raviks, ning neid aineid sisaldav farmatseutiline kompositsioon |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1121131A2 (xx) |
| JP (1) | JP2002527469A (xx) |
| KR (1) | KR20010072878A (xx) |
| CN (1) | CN1367697A (xx) |
| AU (1) | AU6472799A (xx) |
| BG (1) | BG105302A (xx) |
| BR (1) | BR9914419A (xx) |
| CA (1) | CA2345767A1 (xx) |
| EE (1) | EE200100136A (xx) |
| HK (1) | HK1039745A1 (xx) |
| HR (1) | HRP20010262A2 (xx) |
| HU (1) | HUP0103781A3 (xx) |
| ID (1) | ID28441A (xx) |
| IL (1) | IL142588A0 (xx) |
| NO (1) | NO20011403D0 (xx) |
| PL (1) | PL348107A1 (xx) |
| SK (1) | SK4592001A3 (xx) |
| TR (1) | TR200101082T2 (xx) |
| WO (1) | WO2000023057A2 (xx) |
| ZA (1) | ZA200103081B (xx) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006201188B2 (en) * | 2001-02-05 | 2007-11-15 | Novartis Ag | New use of iloperidone |
| GB0102841D0 (en) * | 2001-02-05 | 2001-03-21 | Novartis Ag | Organic compounds |
| CA2463158C (en) | 2001-10-30 | 2013-07-30 | Novartis Ag | Depot formulations of iloperidone and a star polymer |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| US20040192754A1 (en) * | 2003-03-24 | 2004-09-30 | Shapira Nathan Andrew | Methods for treating idiopathic hyperhidrosis and associated conditions |
| TW200501962A (en) * | 2003-04-01 | 2005-01-16 | Novartis Ag | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| WO2005065645A2 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
| JP2008523058A (ja) * | 2004-12-10 | 2008-07-03 | アボット・ラボラトリーズ | 縮合ビシクロ複素環置換キヌクリジン誘導体 |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| DK2091948T3 (da) | 2006-11-30 | 2012-07-23 | Probiodrug Ag | Nye inhibitorer af glutaminylcyclase |
| AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| MX2007008642A (es) * | 2007-07-16 | 2009-02-25 | World Trade Imp Export Wtie Ag | Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias. |
| CA2789014C (en) | 2010-02-09 | 2019-01-15 | Michela Gallagher | Methods and compositions for improving cognitive function |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| EA022420B1 (ru) | 2010-03-10 | 2015-12-30 | Пробиодруг Аг | Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
| JP6899043B2 (ja) | 2015-05-22 | 2021-07-07 | エージンバイオ， インコーポレイテッド | レベチラセタムの持続放出性医薬組成物 |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| DK0584185T3 (da) * | 1991-05-14 | 2000-02-07 | Ernir Snorrason | Behandling af træthedssyndrom med cholinesteraseinhibitorer |
| JP4640888B2 (ja) * | 1997-08-11 | 2011-03-02 | ザ ユニヴァーシティー オブ サウス フロリダ | 神経精神性疾患用ニコチンアンタゴニスト |
| WO1999052519A2 (en) * | 1998-04-14 | 1999-10-21 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
-
1999
- 1999-10-12 CA CA002345767A patent/CA2345767A1/en not_active Abandoned
- 1999-10-12 EE EEP200100136A patent/EE200100136A/xx unknown
- 1999-10-12 PL PL99348107A patent/PL348107A1/xx unknown
- 1999-10-12 AU AU64727/99A patent/AU6472799A/en not_active Abandoned
- 1999-10-12 ID IDW20010828A patent/ID28441A/id unknown
- 1999-10-12 HU HU0103781A patent/HUP0103781A3/hu unknown
- 1999-10-12 SK SK459-2001A patent/SK4592001A3/sk unknown
- 1999-10-12 TR TR2001/01082T patent/TR200101082T2/xx unknown
- 1999-10-12 KR KR1020017002286A patent/KR20010072878A/ko not_active Withdrawn
- 1999-10-12 WO PCT/EP1999/007804 patent/WO2000023057A2/en not_active Ceased
- 1999-10-12 HR HR20010262A patent/HRP20010262A2/hr not_active Application Discontinuation
- 1999-10-12 CN CN99812184A patent/CN1367697A/zh active Pending
- 1999-10-12 HK HK02100158.6A patent/HK1039745A1/zh unknown
- 1999-10-12 IL IL14258899A patent/IL142588A0/xx unknown
- 1999-10-12 JP JP2000576832A patent/JP2002527469A/ja not_active Withdrawn
- 1999-10-12 BR BR9914419-0A patent/BR9914419A/pt not_active IP Right Cessation
- 1999-10-12 EP EP99952580A patent/EP1121131A2/en not_active Withdrawn
-
2001
- 2001-03-01 BG BG105302A patent/BG105302A/xx unknown
- 2001-03-20 NO NO20011403A patent/NO20011403D0/no not_active Application Discontinuation
- 2001-04-12 ZA ZA200103081A patent/ZA200103081B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20010262A2 (en) | 2002-06-30 |
| JP2002527469A (ja) | 2002-08-27 |
| WO2000023057A3 (en) | 2000-07-27 |
| NO20011403L (no) | 2001-03-20 |
| PL348107A1 (en) | 2002-05-06 |
| ID28441A (id) | 2001-05-24 |
| CN1367697A (zh) | 2002-09-04 |
| CA2345767A1 (en) | 2000-04-27 |
| BG105302A (en) | 2001-11-30 |
| AU6472799A (en) | 2000-05-08 |
| EP1121131A2 (en) | 2001-08-08 |
| BR9914419A (pt) | 2001-06-26 |
| HUP0103781A3 (en) | 2003-09-29 |
| KR20010072878A (ko) | 2001-07-31 |
| TR200101082T2 (tr) | 2001-09-21 |
| IL142588A0 (en) | 2002-03-10 |
| NO20011403D0 (no) | 2001-03-20 |
| SK4592001A3 (en) | 2001-12-03 |
| HK1039745A1 (zh) | 2002-05-10 |
| HUP0103781A2 (hu) | 2002-03-28 |
| WO2000023057A2 (en) | 2000-04-27 |
| ZA200103081B (en) | 2002-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200100136A (et) | Atsetüülkoliini esteraasi inhibiitori ja psühhoosivastase toimeaine kasutamine ravimi valmistamiseks, mis on ette nähtud kognitsiooni- ja psühhoosihäirete raviks, ning neid aineid sisaldav farmatseutiline kompositsioon | |
| EE04613B1 (et) | Sahhariidijääkidega asendatud 1,4-bensotiasepiin-1,1-dioksiidi derivaadid, meetod nende valmistamiseks, ühendite kasutamine ning neid sisaldav ravim | |
| HUP0103856A3 (en) | Pharmaceutical composition for the treatment of acute disorders | |
| AR028426A1 (es) | Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfunsion cognitiva en un mamifero | |
| NO20006630L (no) | Farmasöytisk sammensetning for behandlingen av diabetes | |
| HUP0302476A3 (en) | Use of acetylcholinesterase inhibitors and gabaainverse agonists for the treatment of cognitive disorders and for preparation of pharmaceutical compositins | |
| IL147217A0 (en) | New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain | |
| PT956858E (pt) | Composicoes farmaceuticas contendo lactobacilos para o tratamento de infeccoes vaginais | |
| EE200200274A (et) | Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon | |
| PL341343A1 (en) | Composition for treating respiratory diseases and dermatoses containing at least one leucotriene antagonist and at least one antihistaminic agent | |
| DE69836008D1 (de) | Zusammensetzung und behandlungsmittel | |
| NO20001001D0 (no) | Poly (ADP-ribose) polymerase ("PARP") inhibitorer, fremgangsmõte og farmasøytiske sammensetninger for behandling av neurale og kardiovaskulære vevskader | |
| DE60023792D1 (de) | Karmin und Karamel enthaltende selbstbräunende Zusammensetzung | |
| EE200100179A (et) | Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks | |
| HUP9802795A3 (en) | Pharmaceutical compositions containing beta-adrenergic agent and anorectic agent for the treatment of corpulence | |
| EE200300167A (et) | Amidoalküülpiperidiini ja -piperasiini derivaadid, neid sisaldav farmatseutiline kompositsioon ningühendite kasutamine närvisüsteemi häirete raviks | |
| CA2284551A1 (en) | New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders | |
| HUP9902405A3 (en) | Pharmaceutical compositions containing a serotonin antagonist for the treatment of the common cold or allergic rhinitis | |
| NO20011695D0 (no) | Farmasöytisk sammensetning med langvarig frigivelse og fremgangsmåte for å frigi farmasöytisk aktivt middel | |
| EP1177798A3 (en) | A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder(ADHD) comprising a nicotine receptor partial agonist and anti-ADHD agent | |
| NZ513650A (en) | Pharmaceutical composition for the treatment of urinary incontinence, motion sickness and vertigo | |
| HUP0301830A3 (en) | Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes | |
| EE04493B1 (et) | Tsüklopenteeni derivaadid, neid sisaldav farmatseutiline kompositsioon ning ühendite kasutamine ravimina inimestel esinevate motiliini retseptoriga seotud häirete raviks | |
| EE200200590A (et) | Bradükardiaalsete toimeainete kasutamine hüpertroofiaga seotud müokardiaalsete haiguste ravimiseks ja uudsed ravimikombinatsioonid | |
| UA66872C2 (uk) | Сполука, яка є памоатом оланзапіну або його сольватом, та спосіб лікування психотичних розладів |